Evonile Pharma Limited relies on external production for 98.87%

Evonile Pharma Limited generated Rs 350.32 crore, or 98.87%, of Fiscal 2026 revenue from operations through third-party manufacturing, while its largest customer contributed Rs 146.17 crore, or 41.2%, of revenue. Evonile has ended arrangements with its Erstwhile Promoter and a major distributor, leaving replacement sourcing and market access as central transition matters.

How dependent is Evonile on third-party manufacturers?

Evonile depends on third parties for all finished pharmaceutical products and does not own or operate manufacturing facilities. Its externally made portfolio includes formulations in pain management, calcium supplementation, gynecology, neurosciences and transplant immunology, produced at sites in Maharashtra, Goa, Karnataka, Daman, Sikkim, Uttarakhand and Switzerland.

Revenue from products made under third-party manufacturing arrangements was Rs 350.32 crore in Fiscal 2026, compared with Rs 355.30 crore in Fiscal 2025. That revenue declined by Rs 4.98 crore year on year, while its share of revenue from operations moved from 99.73% in Fiscal 2025 to 98.87% in Fiscal 2026, leaving nearly all sales dependent on external production.

Evonile identifies production disruption, quality issues, regulatory action, contractual disputes, raw-material availability and transport delays as risks of this operating model. The company also says its oversight of product quality, storage and distribution may be limited because manufacturers and their suppliers operate outside its direct control.

How did Evonile's supplier concentration change?

Evonile purchased Rs 111.80 crore of stock-in-trade from the Erstwhile Promoter in Fiscal 2026, up from Rs 82.24 crore in Fiscal 2025. The supplier group's portion of total stock-in-trade purchases rose to 53.1% from 41.3%, while total purchases increased to Rs 210.58 crore from Rs 199.07 crore.

The share purchase agreement, or SPA, terminated existing arrangements between Evonile and the Erstwhile Promoter after the change in control. Evonile now sources products from new third parties, including Novartis Pharma Services AG, under arrangements granting exclusive rights to import, distribute and sell specified pharmaceutical products in India for specified periods.

These arrangements typically contain conditions, restrictions and termination rights, according to Evonile. The company says a loss of exclusivity, a reduced allocation, unfavourable pricing, lower product quality or non-renewal could affect its supply and market position, particularly after its Fiscal 2026 procurement concentration with the Erstwhile Promoter exceeded half of stock-in-trade purchases.

Evonile also says some supplier arrangements lack monetary caps and time limits on its indemnification obligations. It may bear costs where products are defective because of incorrect specifications it provides or a breach by the company, adding a contractual liability exposure to its reliance on third-party production.

What import and currency exposure does Evonile report?

Evonile reported imports of Rs 111.80 crore in Fiscal 2026, equivalent to 53.1% of stock-in-trade purchases, compared with Rs 82.24 crore and 41.3% in Fiscal 2025. The company sources through manufacturers in India and Switzerland, and says imports expose it to customs duties and pricing restrictions.

Foreign-currency payables were Rs 29.68 crore as of March 31, 2026, and Evonile says it did not hedge those payables. A rupee depreciation would increase the cost of imported products, creating a cost risk alongside the company's distribution arrangements for products sourced from Switzerland.

Evonile imports, supplies and distributes specialty and prescription pharmaceutical products, including products in transplant immunology and neuroscience that may require controlled storage, cold-chain handling and end-to-end traceability. It says a failure by carrying and forwarding agents, or CFAs, to maintain specified conditions could lead to spoilage, write-offs, recalls or regulatory action.

The company reported that products were recalled in Fiscal 2026 following tests by Karnataka Health Authorities that found they did not meet certain standards. Evonile does not maintain product liability insurance and says any losses, costs or liabilities from product claims, safety alerts or recalls would have to be borne by the company.

How concentrated is Evonile's customer revenue?

Evonile's largest customer contributed Rs 146.17 crore, or 41.2% of revenue from operations, in Fiscal 2026, down from Rs 162.69 crore, or 45.6%, in Fiscal 2025. The contribution fell by Rs 16.52 crore and the revenue share declined by 4.4 percentage points, but one customer still supplied more than two-fifths of annual revenue.

Evonile's top 10 customers accounted for 60.8% of revenue from operations in Fiscal 2026, compared with 63.7% in Fiscal 2025. This 2.9-percentage-point decline indicates lower concentration among the top 10 customers, although the company states that it continues to derive a substantial portion of revenue from a limited number of key customers.

The company says the recent termination of a distribution and promotion agreement with a major distributor has reduced dependency on certain key customers and related concentration risks significantly. However, Evonile must re-acquire and secure market access for products for which the distributor had rights to promote, distribute and sell.

Are Evonile's customer orders contractually committed?

Evonile generally has no long-term supply agreements or firm volume commitments with customers. Distributors and stockists place individual purchase orders, under which unit pricing, delivery schedules, volumes and other commercial terms are ordinarily set for each transaction.

Evonile also supplies institutional and government customers, but says there is no assurance that order frequency, volume or value in a future period will match prior periods. It identifies commercial disputes, changing quality specifications, technology standards and customer financial distress as potential reasons for a decline in orders.

After control changed on July 29, 2026, Evonile began devising growth strategies under its new promoters and reconstituted management. These include building a therapy-aligned, divisionalised field force across metro, tier-2 and tier-3 markets rather than relying on a partner-led distribution model.

Management says the strategy includes expansion in cardio-metabolic therapy, launches within existing therapy areas, and acquisitions of large chronic-therapy brands and complementary brands in orthopedics, gynecology and neurology. The Board approved acquisition of the Minipress and Minipres trademarks and related Indian intellectual property rights on September 7, 2026, while Evonile notes that recruitment, partnerships and new therapy investments may create upfront costs.

Conclusion

Evonile's Fiscal 2026 disclosures show linked dependence on outside manufacturers, imports and a limited customer base. Third-party-made products produced 98.87% of revenue from operations, imports accounted for 53.1% of stock-in-trade purchases, and the largest customer generated 41.2% of revenue. The termination of historic arrangements changes the company from dependence on the Erstwhile Promoter toward new supply and distribution relationships.

What to watch next is execution of Evonile's post-July 29, 2026 plan to build its own therapy-aligned field force, secure market access following the major distributor agreement's termination, and operate new third-party arrangements. The company also disclosed unhedged foreign-currency payables of Rs 29.68 crore as of March 31, 2026, making changes in import sourcing and currency exposure relevant to that transition.